BioTech Health X

Cel-Sci Corporation recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor response and extended overall survival in locally advanced head and neck cancer patients.

On September 10, 2022, Dr. Philip Lavin, a biostatistician with 80 U.S. Food and Drug Administration approvals/clearances, and Dr. József Tímár, Professor and Director of the Central Pathology Laboratory at Semmelweis Egyetem presented poster presentations at the ESMO - European Society for Medical Oncology annual Congress in Paris, France.

CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022 CEL-SCI Phase 3 Multikine ESMO 2022 Poster Presentations from Dr. Philip Lavin & Dr. József Tímár show groundbreaking response & extended overall survival.

EF Hutton has recently initiated a BUY on Cel-Sci Corporation with a price target of $17.00 citing opportunities for growth as a pre-surgery immunotherapy candidate for cancer patients and upcoming near-term catalysts for the company.

EF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News Table of Contents Hide About Cel-Sci CorporationEF Hutton Analyst Tim Moore Coverage of Cel-SciEF Hutton Key Points for…